by Terry Chrisomalis Valeant Pharmaceuticals Intl Inc On November 18, 2015, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) had received approval for two new indications of …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced the appointment of Michael J. Parini to the role of Executive Vice President and Chief Legal Officer.
In a research note issued Friday, Maxim analyst Jason McCarthy reiterated a Hold rating on shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), after the …
In a research report released Friday, Mizuho Securities analyst Irina Rivkind Koffler reiterated a Buy rating on shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced that the European Commission has granted Marketing Authorization for ORKAMBI® (lumacaftor/ivacaftor), the first medicine to treat the …
The biotechnology sector remains busy at the midpoint of the fourth quarter. This week, analysts remain bullish on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) due to …
Cowen remains bullish on Intercept Pharmaceuticals Inc (NASDAQ:ICPT) as the company designs Phase 2 and 3 trials for its pipeline drug aimed to …
Although ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) does not have any approved drugs, Roth Capital remains bullish on its pipeline and impending Phase III trials …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stated that 1,297,399 shares pledged to Goldman Sachs to secure loans made to chairman and chief executive officer …
Analysts are weighing in on the Biopharmaceutical giant Celgene Corporation (NASDAQ:CELG) and controversial drug giant Valeant Pharmaceuticals Intl Inc (NYSE:VRX), as shares of both companies fell …
